Rheumatoid arthritis panel (14 antigens)

Autoimmune diseases are one of the most mysterious and complex problems of modern medicine. They arise when the body's immune system attacks its own cells and tissues, viewing them as foreign agents. Among these diseases, rheumatoid arthritis, systemic lupus erythematosus, and scleroderma are among the most common.

To properly diagnose and monitor autoimmune diseases, doctors use various methods, one of which is the rheumatology panel. This panel consists of 14 antigens that help determine the presence of an autoimmune process in the body and establish a specific diagnosis.

The composition of the rheumatology panel includes the following antigens:

1. Rheumatoid factor (RF) is an antibody that is often found in rheumatoid arthritis. Elevated levels of RF may indicate an exacerbation of the disease.
2. Antinuclear antibodies (ANA) – their elevated levels can be a sign of systemic lupus erythematosus, lupus, and other diseases.
3. Antibodies to cyclic citrullinated peptide (anti-CCP) – their elevated levels indicate possible rheumatoid arthritis.
4. Antibodies to the nuclear antigen RNP (anti-RNP) – this may be an indicator of systemic lupus erythematosus.
5. Antibodies to DNA (anti-dsDNA) – their elevated levels are often found in patients with lupus.
6. Antibodies to nuclear antigens Sm (anti-Sm) – their presence may be an indicator of lupus.
7. Antibodies to neutrophil cytoplasmic antigens (ANCA) – these may be associated with vasculitis.
8. Antibodies to glomerular basement membrane (anti-GBM) – may indicate glomerulonephritis.
9. Antiphospholipid antibodies (anticardiolipin, beta-2-glycoprotein antibodies) – these may be associated with antiphospholipid syndrome.
10. Antibodies to Scl-70 – their elevated level indicates possible scleroderma.
11. Anti-centromere antibodies – this may be an indicator of systemic scleroderma.
12. Antibodies to Jo-1 – their presence may be a sign of dermatomyositis.
13. Antibodies to nuclear antigen peptides (anti-histone) – may be associated with lupus and some other diseases.
14. Antitrypsin antibodies (anti-PM-Scl) – these may be associated with systemic scleroderma.

The rheumatology panel helps doctors determine which antigens are present in a patient and use this to make a diagnosis. It is important to note that the results of the rheumatology panel are always evaluated in the context of clinical symptoms and other tests.

Conclusion: The rheumatology panel is an important tool in the diagnosis of autoimmune diseases, as well as in determining the effectiveness of treatment and disease control. It allows doctors to more accurately and individually prepare a treatment plan for each patient, which contributes to improving the quality of life and prognosis for patients with autoimmune diseases.